Study of Oral Treatments for Hepatitis C

In Phase 1 of this study, consented subjects will be randomized to 1 of the following 3 HCV
treatments:

1) Harvoni® 2)Viekira Pak™ 3)Zepatier™ (The addition of Ribavirin and the length of treatment
will be determined by the provider). In Phase 2 of this study, consented subjects will be
randomized to 1 of 2 FDA approved HCV treatments: 1)1) Harvoni® or 3)Zepatier™. Both Phase 1
and Phase 2 subjects will have up to 1 tablespoon of blood drawn for HCV resistance testing
and future biorepository testing (if subject provides additional consent). The results of
testing will determine whether a genotype 1a subject will be provided 12 or 16 wks of
Zepatier (if randomized to Zepatier).

Following randomization, subjects will complete patient reported outcome questionnaires via
electronic device or telephone. Following randomization, subjects will be asked to complete
surveys again at Wk 4 of treatment, End of Treatment, 1 and 3 year post treatment. Subjects
standard medical care will continue. Test results and medical records throughout treatment
and for up to 3 years post treatment will be collected.

Inclusion Criteria:

- HCV Genotype 1a or 1b

- Adult patients (age 18 years or older)

- Patients being prescribed HCV treatment who can begin treatment with any of the three
HCV treatments being studied (Harvoni, Viekira Pak (Phase 1 only), or Zepatier)

Exclusion Criteria:

- Inability to provide written informed consent

- HARVONI® is not a covered drug on benefits formulary

- Current or historical evidence of hepatic decompensation (variceal bleeding, hepatic
encephalopathy, or ascites)

- Child Pugh (CTP) B or C Cirrhosis (documented CTP calculation is required)

- Pregnant or breastfeeding women